Nuritas Scientific Officer Presents at Brazil’s Federal Council of Medicine on Peptide Discovery

Dr. Sanja Trajkovic brings Nuritas clinically validated bioactive peptides to the institution that sets Brazil’s evidence standard for medical practice

Dublin, Ireland – Nuritas, the biotech company pioneering the discovery and clinical validation of bioactive peptides from natural food sources, announced the participation of Dr. Sanja Trajkovic, Head of Proteomics and Analytical Science and Head of Partnerships, as a keynote speaker at an event hosted by the Federal Council of Medicine (Conselho Federal de Medicina, CFM) in Brasília, Brazil. Her presentation, “The Use of Artificial Intelligence in the Development of Bioactive Peptides,” brought Nuritas science to the body that governs medical practice standards across Latin America’s largest healthcare market.

“Presenting at the CFM means highlighting Nuritas science and strengthening the power of clinical validation on a reputable space,” said Dr. Trajkovic. “In a country that is aging fast and carrying a heavy metabolic burden, winning over that audience is what food-derived peptides as an evidence-based option for physicians and nutritionists.”

Her presentation highlighted two commercially available ingredients developed through Nuritas AI platform: PeptiStrong®, a fava bean-derived peptide clinically studied for muscle health, and PeptiSleep™, validated for cortisol reduction, HRV improvement, and sleep quality.

Reframing What Peptides Mean in a Clinical Setting

A central theme of the presentation was the distinction between the injectable, compounded peptide therapies that regulators increasingly scrutinize and Nuritas distinct class of orally consumed bioactive peptide hydrolysates, ingredients that carry GRAS safety review and are backed by published, peer-reviewed clinical trials. That distinction matters enormously in a market where, as Dr. Trajkovic noted, a flood of unverified products has made physicians and nutritionists appropriately defensive about the entire category.

“The flood of half-truths and unproven supplements online is worth fighting against with real evidence,” she said. “Bringing clinically validated, food-derived peptides to Brazil’s medical establishment means being trusted to make genuinely tested health science accessible to people in a country where the need is large and growing.”

Audience questions centered on how the Magnifier platform generates predictions and how Nuritas validates those predictions in the laboratory, a line of inquiry Dr. Trajkovic welcomed. The company’s position is clear: AI identifies candidate peptides, narrowing the field from millions of possibilities to a focused set of hundreds for laboratory testing. Only peptides that clear in vitro validation are considered discovered, and only those advance to human clinical trials. “AI only predicts,” she emphasized. “The essential step is validation.”